
    
      54 patients who meet the inclusion criteria will receive Docetaxel (60-75mg/m2, every 3
      weeks) or nab-Paclitaxel （125mg/m2，every 3 weeks）combined with Toripalimab( 240mg,every 3
      weeks）for 4-8 cycles until the disease progresses or intolerable toxicity.
    
  